Abstract
Purpose :
To evaluate the effect of sustained subtenon drug delivery approach as adjunctive therapy for treating experimental Staphylococcus aureus endophthalmitis.
Methods :
Twenty adult New Zealand white rabbits of either gender weighting 2.5-3.0 kg were randomly assigned to the subtenon drug delivery assisted treating group and the control group. Randomly one eye of the rabbits were received an intraocular injection of 100 colony-forming units (CFU) of Staphylococcus aureus. 24 hours after inoculation the subtenon drug delivery assisted treating group was received the combined treatment of demethylvancomycin intraocular injection for once and sustained subtenon demethylvancomycin infusion with the flow rate of 0.1ml/h for 7 hours daily through an simply modified auto drug infusion pump. The control group was only received demethylvancomycin intraocular injection for once. Each eye was observed by slit-lamp examination and funduscopy and clinic observation scores were recorded every day. Vitreous samples were collected and cultured for bacteria counting at day 1, day 3 day 5 and day 7 of treatment.
Results :
the clinic observation scores of the subtenon drug delivery assisted treating group were obviously lower than the control group. The difference between two groups was statistically significant (ANOVA ; F=15.126, P=0.001). The peak value of the subtenon drug delivery assisted treating group was 27.40±5.02 which appeared at day 5, while the peak value of the control group was 19.80±4.13 which appeared at day 3. The positive rates of bacteria culture of the subtenon drug delivery assisted treating group and the control group were 42.5% and 27.5%. The difference of bacterial counting rank between the two groups was statistically significant (rank sum test; Z=-2.603, p=0.013).
Conclusions :
Sustained subtenon drug delivery assisted intraocular injection was more effective for treating Staphylococcus aureus endophthalmitis, which indicated that the Sustained subtenon drug delivery approach was an promising adjunctive therapy for treating severe endophthalmitis.
This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.